Printer Friendly

Daiichi Pharmaceutical and Celestar Lexico-Sciences Completes Joint Research on Genome Drug.

Tokyo, Japan, Dec 5, 2005 - (JCN) - Daiichi Sankyo announced on December 5 that its wholly owned subsidiary Daiichi Pharmaceutical has successfully completed a 5-year joint research project it carried out with Celestar Lexico-Sciences (CLS) with significant results.

Using CLS' proprietary in silico prediction technology, the collaboration has identified more than 220 protein-protein interactions, of which 44 disease-related interactions are currently patent pending.

Moreover, one of the results, "Activation of Telomerase by mitogen-activated protein kinase-activated protein kinase 3" was presented at the 64th Annual Meeting of the Japanese Cancer Association. The result is expected to serve a drug discovery target for the treatment of cancer.

Going forward, Daiichi Pharmaceutical will proceed with research on the newly-discovered protein-protein interactions with a view to leveraging them in the development of products.

Meanwhile, CLS plans to combine the in silico prediction technology with its proprietary large-scale in situ Hybridization (LisH) technique for applications in the drug target discovery and the safety evaluation of compounds while improving its technological capabilities.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Dec 6, 2005
Words:175
Previous Article:Kobayashi Pharmaceutical Confirms That Peppermint-Containing Food Helps Alleviate Atopic Dermatitis.
Next Article:Toray, DNA Chip Research to Co-develop High-performance DNA Chip.
Topics:


Related Articles
HUMAN GENOME/AVENTIS BEHRING TO DEVELOP PLASMA PROTEIN.
454 LIFE SCIENCES GETS GENOME LICENSE FROM PYROSEQUENCING.
UCB Japan, Daiichi Pharmaceutical to Reinforce Their Collaboration for Antiallergic Agent Zyrtec.
Daiichi Pharmaceutical Acquires Daiichi Suntory Pharma As Wholly Owned Subsidiary.
Sankyo to Supply Hyperlipidemia Drug Pravastatin in US.
Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of Daiichi Pharmaceutical.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters